|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bray F, Ferlay J, Soerjomataram I, Siegel
RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN
estimates of incidence and mortality worldwide for 36 cancers in
185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Mondello P, Cuzzocrea S and Mian M: Pim
kinases in hematological malignancies: Where are we now and where
are we going? J Hematol Oncol. 7:952014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Warfel NA and Kraft AS: PIM kinase (and
Akt) biology and signaling in tumors. Pharmacol Ther. 151:41–49.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Narlik-Grassow M, Blanco-Aparicio C and
Carnero A: The PIM family of serine/threonine kinases in cancer.
Med Res Rev. 34:136–159. 2014. View Article : Google Scholar
|
|
6
|
Zhang Y, Wang Z, Li X and Magnuson NS: Pim
kinase-dependent inhibition of c-Myc degradation. Oncogene.
27:4809–4819. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Nair JR, Caserta J, Belko K, Howell T,
Fetterly G, Baldino C and Lee KP: Novel inhibition of PIM2 kinase
has significant anti-tumor efficacy in multiple myeloma. Leukemia.
31:1715–1726. 2017. View Article : Google Scholar :
|
|
8
|
Grundler R, Brault L, Gasser C, Bullock
AN, Dechow T, Woetzel S, Pogacic V, Villa A, Ehret S, Berridge G,
et al: Dissection of PIM serine/threonine kinases in
FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of
CXCL12-CXCR4-mediated homing and migration. J Exp Med.
206:1957–1970. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Adam M, Pogacic V, Bendit M, Chappuis R,
Nawijn MC, Duyster J, Fox CJ, Thompson CB, Cools J and Schwaller J:
Targeting PIM kinases impairs survival of hematopoietic cells
transformed by kinase inhibitor-sensitive and kinase
inhibitor-resistant forms of Fms-like tyrosine kinase 3 and
BCR/ABL. Cancer Res. 66:3828–3835. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Brault L, Gasser C, Bracher F, Huber K,
Knapp S and Schwaller J: PIM serine/threonine kinases in the
pathogenesis and therapy of hematologic malignancies and solid
cancers. Haematologica. 95:1004–1015. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Keane NA, Reidy M, Natoni A, Raab MS and
O’Dwyer M: Targeting the pim kinases in multiple myeloma. Blood
Cancer J. 5:e3252015. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
van der Lugt NM, Domen J, Verhoeven E,
Verhoeven E, Linders K, van der Gulden H, Allen J and Berns A:
Proviral tagging in E mu-myc transgenic mice lacking the Pim-1
proto-oncogene leads to compensatory activation of Pim-2. EMBO J.
14:2536–2544. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Allen JD, Verhoeven E, Domen J, van der
Valk M and Berns A: Pim-2 transgene induces lymphoid tumors,
exhibiting potent synergy with c-myc. Oncogene. 15:1133–1141. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hammerman PS, Fox CJ, Cinalli RM, Xu A,
Wagner JD, Lindsten T and Thompson CB: Lymphocyte transformation by
Pim-2 is dependent on nuclear factor-kappaB activation. Cancer Res.
64:8341–8348. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lu J, Zavorotinskaya T, Dai Y, Niu XH,
Castillo J, Sim J, Yu J, Wang Y, Langowski JL, Holash J, et al:
Pim2 is required for maintaining multiple myeloma cell growth
through modulating TSC2 phosphorylation. Blood. 122:1610–1620.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Asano J, Nakano A, Oda A, Amou H, Hiasa M,
Takeuchi K, Miki H, Nakamura S, Harada T, Fujii S, et al: The
serine/threo-nine kinase Pim-2 is a novel anti-apoptotic mediator
in myeloma cells. Leukemia. 25:1182–1188. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Jimenez-Garcia MP, Lucena-Cacace A,
Robles-Frias MJ, Ferrer I, Narlik-Grassow M, Blanco-Aparicio C and
Carnero A: Inflammation and stem markers association to PIM1/PIM2
kinase-induced tumors in breast and uterus. Oncotarget.
8:58872–58886. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Wang Z, Zhang Y, Gu JJ, Davitt C, Reeves R
and Magnuson NS: Pim-2 phosphorylation of p21(Cip1/WAF1) enhances
its stability and inhibits cell proliferation in HCT116 cells. Int
J Biochem Cell Biol. 42:1030–1038. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Morishita D, Katayama R, Sekimizu K,
Tsuruo T and Fujita N: Pim kinases promote cell cycle progression
by phosphorylating and down-regulating p27Kip1 at the
transcriptional and posttran-scriptional levels. Cancer Res.
68:5076–5085. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yan B, Zemskova M, Holder S, Chin V, Kraft
A, Koskinen PJ and Lilly M: The PIM-2 kinase phosphorylates BAD on
serine 112 and reverses BAD-induced cell death. J Biol Chem.
278:45358–45367. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Fox CJ, Hammerman PS, Cinalli RM, Master
SR, Chodosh LA and Thompson CB: The serine/threonine kinase Pim-2
is a transcriptionally regulated apoptotic inhibitor. Genes Dev.
17:1841–1854. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Hospital MA, Jacquel A, Mazed F, Saland E,
Larrue C, Mondesir J, Birsen R, Green AS, Lambert M, Sujobert P, et
al: RSK2 is a new Pim2 target with pro-survival functions in
FLT3-ITD-positive acute myeloid leukemia. Leukemia. 32:597–605.
2018. View Article : Google Scholar
|
|
23
|
Ramachandran J, Santo L, Siu KT, Panaroni
C and Raje N: Pim2 is important for regulating DNA damage response
in multiple myeloma cells. Blood Cancer J. 6:e4622016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Yang T, Ren C, Qiao P, Han X, Wang L, Lv
S, Sun Y, Liu Z, Du Y and Yu Z: PIM2-mediated phosphorylation of
hexokinase 2 is critical for tumor growth and paclitaxel resistance
in breast cancer. Oncogene. 37:5997–6009. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Musiani D, Hammond DE, Cirillo L, Erriquez
J, Olivero M, Clague MJ and Di Renzo MF: PIM2 kinase is induced by
cispl-atin in ovarian cancer cells and limits drug efficacy. J
Proteome Res. 13:4970–4982. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Uddin N, Kim RK, Yoo KC, Kim YH, Cui YH,
Kim IG, Suh Y and Lee SJ: Persistent activation of STAT3 by
PIM2-driven positive feedback loop for epithelial-mesenchymal
transition in breast cancer. Cancer Sci. 106:718–725. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Narlik-Grassow M, Blanco-Aparicio C,
Cecilia Y, Peregrina S, Garcia-Serelde B, Muñoz-Galvan S, Cañamero
M and Carnero A: The essential role of PIM kinases in sarcoma
growth and bone invasion. Carcinogenesis. 33:1479–1486. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Chen J and Yang X: The role of Pim-2 in
apoptotic signal transduction pathway of hepatocellular carcinoma.
Int Surg J. 4:13802017. View Article : Google Scholar
|
|
29
|
Ren K, Zhang W, Shi Y and Gong J: Pim-2
activates API-5 to inhibit the apoptosis of hepatocellular
carcinoma cells through NF-kappaB pathway. Pathol Oncol Res.
16:229–237. 2010. View Article : Google Scholar
|
|
30
|
Gong J, Wang J, Ren K, Liu C, Li B and Shi
Y: Serine/threonine kinase Pim-2 promotes liver tumorigenesis
induction through mediating survival and preventing apoptosis of
liver cell. J Surg Res. 153:17–22. 2009. View Article : Google Scholar
|
|
31
|
Ren K, Duan W, Shi Y, Li B, Liu Z and Gong
J: Ectopic overexpression of oncogene Pim-2 induce malignant
transformation of nontumorous human liver cell line L02. J Korean
Med Sci. 25:1017–1023. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar
|
|
33
|
Hobel S, Koburger I, John M, Czubayko F,
Hadwiger P, Vornlocher HP and Aigner A: Polyethylenimine/small
interfering RNA-mediated knockdown of vascular endothelial growth
factor in vivo exerts anti-tumor effects synergistically with
Bevacizumab. J Gene Med. 12:287–300. 2010.PubMed/NCBI
|
|
34
|
Liu Z, Liu H, Yuan X, Wang Y, Li L, Wang
G, Song J, Shao Z and Fu R: Downregulation of Pim-2 induces cell
cycle arrest in the G0/G1 phase via the p53-non-dependent p21
signaling pathway. Oncol Lett. 15:4079–4086. 2018.PubMed/NCBI
|
|
35
|
Yew TL, Chiu FY, Tsai CC, Chen HL, Lee WP,
Chen YJ, Chang MC and Hung SC: Knockdown of p21(Cip1/Waf1) enhances
proliferation, the expression of stemness markers, and osteogenic
potential in human mesenchymal stem cells. Aging Cell. 10:349–361.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Nawijn MC, Alendar A and Berns A: For
better or for worse: The role of Pim oncogenes in tumorigenesis.
Nat Rev Cancer. 11:23–34. 2011. View Article : Google Scholar
|
|
37
|
Levy D, Davidovich A, Zirkin S, Frug Y,
Cohen AM, Shalom S and Don J: Activation of cell cycle arrest and
apoptosis by the proto-oncogene Pim-2. PLoS One. 7:e347362012.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Adam K, Cartel M, Lambert M, David L, Yuan
L, Besson A, Mayeux P, Manenti S and Didier C: A PIM-CHK1 signaling
pathway regulates PLK1 phosphorylation and function during mitosis.
J Cell Sci. 131:pii: jcs213116. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Kreuz S, Holmes KB, Tooze RM and Lefevre
PF: Loss of PIM2 enhances the anti-proliferative effect of the
pan-PIM kinase inhibitor AZD1208 in non-Hodgkin lymphomas. Mol
Cancer. 14:2052015. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Pellegrino R, Calvisi DF, Ladu S, Ehemann
V, Staniscia T, Evert M, Dombrowski F, Schirmacher P and Longerich
T: Oncogenic and tumor suppressive roles of polo-like kinases in
human hepatocellular carcinoma. Hepatology. 51:857–868.
2010.PubMed/NCBI
|
|
41
|
Liu Z, Sun Q and Wang X: PLK1, A potential
target for cancer therapy. Transl Oncol. 10:22–32. 2017. View Article : Google Scholar
|
|
42
|
Waisberg J and Saba GT: Wnt-/-β-catenin
pathway signaling in human hepatocellular carcinoma. World J
Hepatol. 7:2631–2635. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Vilchez V, Turcios L, Marti F and Gedaly
R: Targeting Wnt/β-catenin pathway in hepatocellular carcinoma
treatment. World J Gastroenterol. 22:823–832. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
de La Coste A, Romagnolo B, Billuart P,
Renard CA, Buendia MA, Soubrane O, Fabre M, Chelly J, Beldjord C,
Kahn A and Perret C: Somatic mutations of the beta-catenin gene are
frequent in mouse and human hepatocellular carcinomas. Proc Natl
Acad Sci USA. 95:8847–8851. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Ding Z, Shi C, Jiang L, Tolstykh T, Cao H,
Bangari DS, Ryan S, Levit M, Jin T, Mamaat K, et al: Oncogenic
dependency on β-catenin in liver cancer cell lines correlates with
pathway activation. Oncotarget. 8:114526–114539. 2017. View Article : Google Scholar
|
|
46
|
Schmucker S and Sumara I: Molecular
dynamics of PLK1 during mitosis. Mol Cell Oncol. 1:e9545072014.
View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Katyal S, Oliver JH III, Peterson MS,
Ferris JV, Carr BS and Baron RL: Extrahepatic metastases of
hepatocellular carcinoma. Radiology. 216:698–703. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Weirauch U, Beckmann N, Thomas M,
Grünweller A, Huber K, Bracher F, Hartmann RK and Aigner A:
Functional role and therapeutic potential of the pim-1 kinase in
colon carcinoma. Neoplasia. 15:783–794. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Kamran MZ, Patil P and Gude RP: Role of
STAT3 in cancer metastasis and translational advances. Biomed Res
Int. 2013:4218212013. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ibrahim AF, Weirauch U, Thomas M,
Grunweller A, Hartmann RK and Aigner A: MicroRNA replacement
therapy for miR-145 and miR-33a is efficacious in a model of colon
carcinoma. Cancer Res. 71:5214–5224. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Hobel S and Aigner A: Polyethylenimines
for siRNA and miRNA delivery in vivo. Wiley Interdiscip Rev Nanomed
Nanobiotechnol. 5:484–501. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Wood H: FDA approves patisiran to treat
hereditary transthyretin amyloidosis. Nat Rev Neurol.
14:5702018.PubMed/NCBI
|
